04 Dec 2023

Shareholder update to review AVA6000 Phase 1a data

Investors | Therapeutics

23 Oct 2023

Issue of Equity and Total Voting Rights

Investors

18 Oct 2023

Block Listing Application to AIM

Investors

05 Oct 2023

Avacta to present promising new data from Affimer^® and pre|CISION^TM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Investors | Therapeutics

29 Sep 2023

Director/PDMR Shareholdings

Investors

28 Sep 2023

Interim Results for the Period Ending 30 June 2023

Investors

20 Sep 2023

Issue of Equity and Total Voting Rights

Investors

20 Sep 2023

Peel Hunt Appointed as Joint Broker

Investors

20 Sep 2023

Appointment of Dr. Christina Coughlin as a consultant

Investors | Therapeutics

19 Sep 2023

Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update

Investors | Therapeutics